Trial of Azedra in high-risk neuroblastoma
CAMBRIDGE, Massachusetts-Molecular Insight Pharmaceuticals, Inc. has initiated a multicenter phase IIa clinical trial of Azedra (Ultratrace iobenguane I-131 or Ultratrace MIBG) for the treatment of children with high-risk neuroblastoma.
CAMBRIDGE, Massachusetts-Molecular Insight Pharmaceuticals, Inc. has initiated a multicenter phase IIa clinical trial of Azedra (Ultratrace iobenguane I-131 or Ultratrace MIBG) for the treatment of children with high-risk neuroblastoma. Azedra is a targeted radiotherapeutic comprised of the known I-131 MIBG molecule radiolabeled using Molecular Insight’s proprietary Ultratrace technology, which removes unnecessary nonradioactive molecules, or cold contaminants, to maximize therapeutic potential. The trial is being coordinated by the New Approaches to Neuroblastoma Therapy (NANT) Consortium, a group of 14 US academic medical centers and children’s hospitals.
